MGMT status (predictive value)

What it is

MGMT methylation status predicts how well a glioblastoma is likely to respond to the chemotherapy drug temozolomide: tumors with a methylated (silenced) MGMT gene respond better. MGMT status is therefore primarily a predictive marker, and it also carries prognostic significance.

Understanding MGMT status (predictive value)

As described earlier, the MGMT gene repairs the DNA damage that temozolomide causes; when MGMT is methylated (silenced), the tumor cannot repair this damage as well, so temozolomide works better. This makes MGMT methylation a predictive marker for temozolomide response, and methylated tumors also tend to have better outcomes (a prognostic effect). The practical value is in guiding treatment, especially in older patients with glioblastoma, where MGMT status can help weigh options (for example, whether temozolomide is likely to add benefit). In standard treatment for younger, fit patients, temozolomide is generally used regardless of MGMT status, but the status still informs prognosis and expectations. MGMT status is an example of a biomarker that is both predictive and prognostic, and it relies on molecular testing of the tumor. Understanding the predictive value of MGMT status clarifies how this marker informs temozolomide use and outlook.

Why it matters

Understanding the predictive value of MGMT status helps patients and families see how this marker guides treatment — predicting temozolomide response and informing prognosis — particularly relevant for older patients' treatment decisions.